Amgen's 10% drop pulled the Dow lower as oil jumped and bonds sat still

Novartis said pelacarsen lowered lipoprotein(a), a blood fat tied to heart risk, exactly as designed, and patients still did not have fewer cardiac events. Amgen is running the same bet with olpasiran. On Tuesday, the first session after Labor Day and a morning Amgen published a positive lung-cancer result, the stock still fell 10%, taking 0.49 percentage points off the Dow industrials fund DIA, which closed 1.13% lower. Brent crude, in the same session, traded as high as $99.45 a barrel after Houthi strikes halted operations at Saudi energy sites. The S&P 500 still closed only 0.6% lower, at 7,674. The Nasdaq-100 fund was nearly unchanged. Long-term Treasurys did not budge.

That is a messy tape, not a clean inflation scare.

Across U.S.-listed ETFs, 1,395 closed up and 3,138 closed down of 4,644 priced. Cap-weighted indexes papered over how wide the weakness ran.

The equal-weight S&P 500 fund lagged its cap-weighted counterpart by 0.49 percentage points. If you hold SPY, Tuesday looked like a modest down day. The rest of the market was worse.

Novartis missed twice, and health care paid

Novartis on Friday, after the close, reported the pelacarsen miss in the Phase 3 Lp(a)HORIZON trial: the drug did not cut a composite of cardiovascular death, heart attack, stroke, and urgent revascularization. Eli Lilly has an Lp(a) candidate too. Monday was Labor Day, so Tuesday was the first session that could price the result. The same morning, Novartis said del-desiran, a myotonic-dystrophy treatment from the company's Avidity acquisition, failed the Phase 3 HARBOR study on its primary endpoint, a timed measure of hand function. U.S.-listed Novartis shares fell 13.9%.

Those are different drugs and different read-throughs, and the funds split them. The U.S. biotechnology fund IBB, where Amgen is an 8.6% position, fell 2.17%; Amgen alone contributed -0.86 percentage points. The more diversified S&P biotech fund XBI fell 1.12%, with Dyne Therapeutics, a 16% loser on the dystrophy result, the largest drag. Health care XLV dropped 2.50%, the worst of the 11 sector funds, and Amgen was only part of it: Eli Lilly, Johnson & Johnson, and AbbVie were lower too. Boston Scientific, a separate story, fell 5.9% after saying a cybersecurity incident that disrupted manufacturing and shipments made it unlikely to meet third-quarter and full-year 2026 forecasts.

The Dow, which weights Amgen by share price, felt the 10% drop more than the S&P 500 did. Nvidia, Apple, and Microsoft, the usual S&P 500 weights, subtracted 0.32 percentage points from SPY among them and still left the index with a 0.6% loss, not a 1% one.

Oil near $99, the 10-year at 4.80%

Saudi Arabia said attacks on energy facilities and utilities in the south started fires and temporarily halted some operations. The Houthis said they had again targeted the Jazan complex, which includes a 400,000-barrel-a-day refinery. Brent was at $99.10 late in the New York afternoon, up 2.9%; West Texas Intermediate was at $94.04, up 2.8%. The oil fund USO gained 2.9%, its fifth-session gain now 9.2%. This was not a one-day spike. It was another day in a rally that has already lifted USO 24% over a month.

Energy stocks did not move as a bloc. The energy sector fund XLE rose 1.1%, led by refiners: Valero contributed 0.17 percentage points, Marathon Petroleum 0.13. SLB and Halliburton, the oilfield-services names, finished lower. Airline fund JETS fell 1.8%. Higher crude and a hit to downstream capacity are not the same trade as a boom in drilling.

If oil near $100 were being priced as a coming rate shock, the bond market would have cheapened. It did not. The 10-year Treasury yield closed at 4.80%.

Inflation-protected Treasurys TIP rose 0.07%, barely more than long Treasurys TLT, which were unchanged on some of their lightest volume in 20 sessions. Intermediate Treasurys IEF slipped 0.10%. High-yield HYG was flat. Gold futures were down 1.6% at $4,405, and GLD closed 1.7% lower, even as the dollar index fell 0.3%. The VIX rose 8.4% to 15.75, a modest bid for protection, not a stress print. New York Fed consumer inflation expectations for August, out at 3 p.m., held at 3.6% and matched the forecast.

Utilities XLU rose 0.9%, a fifth straight gain. Staples XLP fell for a third session, on their heaviest volume in 20. That is not a textbook flight to defense.

Intel and AMD kept technology in the green

Technology XLK rose 0.3%, a third straight gain, because the middle of the chip stack offset the giants. Intel jumped 9.1% after a report that it planned a 10% increase in processor prices in early October, and after Northland Securities raised the stock to outperform. The five-session gain is now 17%. Advanced Micro Devices rose 5.9%. In the Nasdaq-100 fund, those two more than offset Nvidia's 2.0% decline. The semiconductor fund SOXX rose 1.6%. None of that made Tuesday a risk-on day. It made the Nasdaq-100 a poor summary of one.

Canada collected, and most of the tape did not

Canada at 12:01 a.m. began collecting retaliatory tariffs of 15%, 25%, or 50% on C$27.6 billion of U.S. goods, matching duties Washington imposed in August, after talks collapsed. Steel, dairy, appliances, farm equipment, electronics, and pulp and paper are on the list.

Materials XLB fell 0.9%, a third straight decline. Industrials XLI slipped 0.5%. Financials XLF dropped 1.4%, with JPMorgan, Visa, Mastercard, and Wells Fargo the largest drags and no company-level event on the scale of Amgen's. Consumer discretionary XLY fell 0.8%.

This was not a heavy-liquidation session in the core index funds. SPY traded at 1.1 times its 20-session median. QQQ was below its own. DIA was among its heaviest 20 sessions, which fits a Dow that had a 10% stock in it. Single-name leverage funds made the loudest prints, as they do on any day with a 9% Intel or a 10% Amgen. They are not the market.

Thursday and Friday bring inflation reports, and the FOMC decision is on September 16. Governor Christopher Waller said last week he would lean toward holding the funds rate if incoming data kept showing progress. "But if inflation comes in hot, I would consider a rate hike," he said. Tuesday priced the Saudi attacks into oil and the Novartis misses into health care. It did not price a duration shock. A hot CPI with Brent still near $99 would be the session this one declined to be.